Related Experiment Video
Updated: Oct 25, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
Yogesh R Suryawanshi1, Autumn J Schulze1
1Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Abstract:
Glioblastoma is one of the most difficult tumor types to treat with conventional therapy options like tumor debulking and chemo- and radiotherapy. Immunotherapeutic agents like oncolytic viruses, immune checkpoint inhibitors, and chimeric antigen receptor T cells have revolutionized cancer therapy, but their success in glioblastoma remains limited and further optimization of immunotherapies is needed. Several oncolytic viruses have demonstrated the ability to infect tumors and trigger anti-tumor immune responses in malignant glioma patients. Leading the pack, oncolytic herpesvirus, first in its class, awaits an approval for treating malignant glioma from MHLW, the federal authority of Japan. Nevertheless, some major hurdles like the blood-brain barrier, the immunosuppressive tumor microenvironment, and tumor heterogeneity can engender suboptimal efficacy in malignant glioma. In this review, we discuss the current status of malignant glioma therapies with a focus on oncolytic viruses in clinical trials. Furthermore, we discuss the obstacles faced by oncolytic viruses in malignant glioma patients and strategies that are being used to overcome these limitations to (1) optimize delivery of oncolytic viruses beyond the blood-brain barrier; (2) trigger inflammatory immune responses in and around tumors; and (3) use multimodal therapies in combination to tackle tumor heterogeneity, with an end goal of optimizing the therapeutic outcome of oncolytic virotherapy.
Insights
Oncolytic viruses show promise for treating glioblastoma by triggering anti-tumor immunity. Strategies are being developed to overcome challenges like the blood-brain barrier and tumor heterogeneity for improved glioblastoma treatment outcomes.
Area of Science:
- Neuro-oncology
- Virology
- Immunotherapy
Background:
- Glioblastoma remains challenging to treat with conventional therapies.
- Immunotherapies offer new avenues but face limitations in glioblastoma.
- Oncolytic viruses demonstrate potential for triggering anti-tumor immune responses in malignant glioma.
Purpose of the Study:
- To review the current status of oncolytic virus therapies for malignant glioma.
- To discuss challenges hindering oncolytic virus efficacy in glioblastoma.
- To explore strategies for optimizing oncolytic virotherapy in malignant glioma.
Main Methods:
- Review of clinical trials involving oncolytic viruses for malignant glioma.
- Analysis of obstacles such as the blood-brain barrier, immunosuppressive tumor microenvironment, and tumor heterogeneity.
- Discussion of strategies to enhance oncolytic virus delivery, immune response induction, and combination therapies.
Main Results:
- Oncolytic herpesvirus is nearing approval in Japan for malignant glioma.
- Key challenges include overcoming the blood-brain barrier and the immunosuppressive tumor microenvironment.
- Strategies focus on improving viral delivery, stimulating anti-tumor immunity, and combining therapies to address tumor heterogeneity.
Conclusions:
- Optimizing oncolytic virotherapy requires overcoming significant biological and physical barriers.
- Multimodal approaches are crucial for enhancing therapeutic outcomes in glioblastoma.
- Further research and strategic development are needed to fully realize the potential of oncolytic viruses in treating malignant glioma.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...